Abstract: CDX-2 is a homeobox gene product essential for intestinal development and differentiation. It can be used as a specific marker of colorectal adenocarcinomas and other tumors with intestinal differentiation, but little is known about its expression in endocrine and neuroendocrine (NE) cells and NE primary and metastatic tumors. Using the Cdx-2-88 monoclonal antibody, we evaluated CDX-2 expression in routine samples of 20 normal endocrine/NE tissues and of 299 samples of well-differentiated NE tumors (WDNET) and high-grade NE carcinomas (NEC) from different sites. For 17 cases, we examined primary and corresponding metastatic lesions. We also examined 8 cytologic samples of liver metastases derived from 4 ileal WDNETs, 1 lung WDNET, and 3 pancreatic endocrine tumors. CDX-2 mRNA expression with RT-PCR technique on frozen material was evaluated in 5 WDNETs. CDX-2 was expressed in normal NE cells of the intestine and gastric fundus. High CDX-2 expression was seen in all ileal and appendiceal WDNET, while low levels were seen in WDNETs from stomach, duodenum, and rectum; no reactivity was seen in other WDNETs. Low levels of CDX-2 expression were seen in one third of nonfunctioning pancreatic WDNET where it was more frequently observed in cases with metastatic disease (P = 0.002). CDX-2 was identified in all cytologic specimens of metastatic ileal WDNETs. CDX-2 mRNA analysis confirmed immunohistochemical results. CDX-2 was expressed at high levels in 81% of intestinal NEC. Unexpectedly, variable levels of expression of CDX-2 were seen also in 39% of NEC of other sites, without any relation with the site of origin. This reactivity frequently overlapped TTF-1 expression, suggesting deregulated expression of homeobox genes in NEC. The restricted pattern of CDX-2 expression may have diagnostic value in the identification of the primary site of a metastatic WDNET. Conversely, a limited diagnostic role is suggested for CDX-2 in NEC because of its frequent expression in nongastrointestinal tumors.
C DX-2 is the product of the Cdx-2 homeobox gene related to the Drosophila melanogaster gene caudal which is essential for the axial patterning and intestinal development of the fruit fly. Three Cdx homeobox genes have been identified in mice (Cdx-1, Cdx-2, and Cdx4), and two have been identified so far in humans (CDX-1 4 and CDX-2 8 ). These genes encode for transcription factors that play an essential role as regulatory proteins for proliferation and differentiation of intestinal epithelial cells in fetal as well as in adult tissues. 5 CDX-1 and CDX-2 are lineage specific: in normal adult human tissues, they are expressed only in colonic and small intestinal epithelium and regulate the expression of several different genes involved in intestinal cell differentiation and metabolism. 14, 22 CDX-2 is a very specific and sensitive marker of colorectal adenocarcinomas, 12 which can be used in the differential diagnosis of metastatic adenocarcinomas of unknown primary sites. 2, 23 Well-differentiated neuroendocrine (NE) tumors (WDNET) are relatively common neoplasms arising mainly in the lung, gastrointestinal tract, and pancreas. WDNETs are able to metastasize to liver, lymph nodes, or other organs. Since WDNETs share similar morphology and overlapping immunohistochemical profiles, these features are not useful for determining the site of origin of a metastatic lesion. Identifying the primary site of WDNET has significant clinical and therapeutic relevance. Similar considerations apply also for high-grade NE carcinomas (NECs). In this context, TTF-1, another homeobox gene, has been proposed for the identification of metastatic lung NE tumors. 6, 16 The possible role of CDX-2 in promoting endocrine differentiation in intestinal epithelial cells and its expression in intestinal NE cells has not been investigated. CDX-2 expression has indeed been described in a limited series of NE intestinal neoplasms, but little information is available about its expression in other NE tumors. 15, 23 In the present study, we evaluated CDX-2 expression in a large series of common and uncommon NE human tumors of different origin, both primary and metastatic as well in normal endocrine cells in different tissues. Our aims were: 1) to evaluate CDX-2 expression in normal intestinal endocrine cells, 2) to delineate the pattern of CDX-2 expression in NE tumors from different sites, and 3) to verify if CDX-2 can be used as a marker in the differential diagnosis of metastatic NE tumors.
MATERIALS AND METHODS

Cases
Twenty samples of formalin-fixed, paraffin-embedded normal endocrine/NE tissues, including hypophysis, thyroid, parathyroid, gastrointestinal and lung tissue, pancreas, paraganglia, adrenal gland, ovary, and testis, were evaluated. A total of 299 cases representative of most NE tumors of different sites, including primary and metastatic lesions, were retrieved from the files of the Departments of Pathology of Belluno, Reggio Emilia, Verona, and Trento. All cases had been previously characterized for NE phenotype and, for pancreatic lesions, for hormone production.
A detailed list of the investigated tumors is shown in Table 1 . In 17 cases, metastatic and corresponding primary NE tumors were available: this series included 11 liver, 5 nodal, and 1 mammary metastases, deriving from lung small cell carcinoma (1 case), lung WDNET (1 case), ileal WDNET (6 cases), gastric and duodenal gastrinomas (2 cases), pancreatic WDNET (6 cases), and poorly differentiated (1 case) NEC.
The 61 pancreatic tumors were classified as functioning (13 cases) and nonfunctioning (48 cases) on the basis of hormone production: 9 cases were positive for insulin, 2 for glucagon, 1 for serotonin, and 1 for multiple hormones. The clinical stage was known in 50 of these cases: 19 presented with metastases and 31 without. For each case, one representative paraffin block was selected and 5-µm sections were cut. We also examined a series of eight cytologic samples obtained by fine needle aspiration of liver nodules, for which surgical resection specimens were available and for which an unequivocal diagnosis was established. The liver metastases were derived from ileal WDNETs (4 cases), lung WDNET (1 case), and pancreatic endocrine tumors (3 cases).
Five cases of WDNET (2 ileal, 2 pancreatic, and 1 pulmonary) for which frozen material was available were also evaluated for CDX-2 mRNA expression, with an RT-PCR technique. One case of colonic carcinoma was used as positive control.
Immunostaining
All cases were immunostained with a StreptABC technique using a monoclonal antibody against CDX-2 (Cdx-2-88, Biogenex, San Ramon, CA, 1:200 dilution).
2 Samples of normal ileal and colonic mucosa were submitted to double immunostainings for chomogranin A (LH2H10, Labvision, Fremont, CA) and CDX-2, using a previously described procedure. 3 Selected cases of high-grade NE tumors were also immunostained for TTF-1 (8G8G3/1, Labvision, Fremont, CA). Heat-induced antigen retrieval was performed using citrate buffer in a microwave oven. Primary antibody was detected using a sensitive Strept-ABC technique with diaminobenzidine development. 3 All stainings were performed with an automatic immunostainer (Biogenex Optimax). Appropriate positive and negative controls were run simultaneously. Papanicolaou stained cytologic samples were bleached, subjected to heat-induced antigen retrieval, and immunostained. Immunostaining was scored semiquantitatively according to the estimated percentage of positive tumor cells, ie, 0 (no staining), 1 (1%-10% reactive cells), 2 (11%-50%), and 3 (51%-100%). Intensity (weak, +; moderate, ++; intense, +++) and pattern (cytoplasmic/nuclear) of staining were also recorded.
RNA Extraction and RT-PCR for CDX-2
Frozen samples were ground by a tissue dismembrator (Mikro-Dismembrator S, B. Braun International, Germany) and RNA were extracted using a guanidine isothiocyanate protocol (TRIzol Reagent GIBCO BRL, Life Technologies, Gaithersburg, MD). Following DNAse treatment, equal amounts of total RNA (1 µg) were reverse transcribed into cDNA using random primers and Superscript First-Strand Synthesis System (GIBCO BRL, Life Technologies) according to manufacturer's instructions. The human Gs␣ gene was used as endog- 
RESULTS
Normal Tissues
In normal tissues, CDX-2 was expressed in the nuclei of almost all intestinal epithelial cells from the duodenum to the rectum, including intestinal endocrine cells as demonstrated by double immunohistochemical staining (Fig. 1) . Normal gastric mucosa was devoid of CDX-2 immunoreactive cells, with the exception of single NE cells in the fundic glands. No reactivity was observed in all other tested endocrine/NE tissues, including pancreatic insulae.
WDNET
In WDNET, CDX-2 was expressed at high levels in all ileal and appendiceal lesions with intense nuclear and moderate cytoplasmic reactivity ( Fig. 2A) . In some cases, dot-like paranuclear staining was also observed (Fig. 2B) . CDX-2 immunoreactivity in NE cell hyperplasias of the stomach (Fig. 3) , WDNETs from the stomach, duodenum, and rectum was usually weak and restricted to a limited percentage of cells. Among pancreatic WDNETs, CDX-2 was seen in one third of nonfunctioning tumors, usually with a low percentage of immunoreactive nuclei and faint staining intensity (Fig. 4) ; no reactivity was seen in functioning tumors. CDX-2 immunoreactivity was more frequently observed in pancreatic WDNET with metastatic disease (P = 0.002, Table 2 ).
No CDX-2 reactivity was seen in NE cell hyperplasias of bronchial mucosa and in lung tumorlets, as well as in all lung WDNETs. No reactivity was observed in paragangliomas (6 cases), pheochromocytomas (4 cases), cortical adenoma (1 case) of the adrenal gland, thyroid (3 follicular, 7 papillary, and 
High-grade NE Tumors
CDX-2 was expressed at high levels in the majority (13 of 16 cases, 81%) of intestinal poorly differentiated NECs. A variable percentage of CDX-2 reacting cells was seen also in 16 of 41 (39%) NECs of other sites, without an apparent relation with the site of origin (Table 3 ; Fig. 5 ). Fifty-one NEC cases were also evaluated for TTF-1 expression (Table 4) . TTF-1 was observed in 3 of 13 (23%) gastrointestinal tumors, in 12 of 23 (52%) nongastrointestinal, nonpulmonary tumors, and in 9 of 13 (69%) lung NECs. Inappropriate expression of these gene products, ie, expression in tumors deriving from organs normally devoid of CDX-2 and/or TTF-1, was observed in 25 of 51 (49%) cases (Table 3) .
Metastatic NE Tumors
In the 17 paired samples of primary and metastatic lesions analyzed, the pattern of immunoreactivity was similar in both sites. Strong and diffuse nuclear and cytoplasmic CDX-2 immunoreactivity was limited to metastatic ileal WDNETs (100% of cases); intermediate/low levels of staining were seen in one of six pancreatic well-differentiated carcinomas, in the single case of pancreatic poorly differentiated carcinoma (2+ in 30%), and in two gastrinomas from stomach and duodenum (1+ in 20% of the cells). 
Fine Needle Aspiration Samples of Hepatic Metastases
CDX-2 immunoreactivity was readily identified in all fine needle aspiration biopsies of ileal WDNETs (Fig. 6 ). Weak and focal staining was present in a single case of pancreatic endocrine carcinoma. No reactivity was seen in the remaining samples.
CDX-2 mRNA Expression
CDX-2 mRNA was expressed in the two samples of ileal WDNETs and in a colon adenocarcinoma used as positive control (Fig. 7) . CDX-2 mRNA was not detectable in two pancreatic and one lung WDNET (Fig. 7) . Gs␣ mRNA levels were constant in all tumors analyzed. mRNA results correlated with the CDX-2 expression at the immunohistochemical level.
DISCUSSION
Our study shows that CDX-2 is expressed in normal endocrine cells of the intestinal tract. We also demonstrate that CDX-2 is expressed in all primary and metastatic WDNET of the ileum and appendix, and in a subset of gastric, colorectal, and pancreatic WDNETs. The absence of CDX-2 in primary and metastatic WDNET of other sites suggests that CDX-2 expression may be used as a marker when the origin of a metastatic WDNET has to be determined. In addition, we observed CDX-2 expression in most NECs of the gastrointestinal tract but, surprisingly, also in a significant subset of NEC of other sites.
CDX-2 plays an important role in proliferation and differentiation of intestinal epithelial cells, where it is normally expressed throughout embryonic and postnatal life. The expression of CDX-2 in enterocytes, goblet, and Paneth cells as well as in NE cells of the human intestine may be interpreted in the light of their hypothesized origin from a common totipotent stem cell. 7, 20 Moreover, the expression of CDX-2 in all NE cells of the gastrointestinal tract in contrast to the lack of expression in NE cells of other organs (eg, bronchial tree) is in keeping with the hypothesis that cells of the dispersed NE system originate from pluripotent cells that differentiate locally under the control of factors unique to a specific site or organ. 18 Data on CDX-2 expression in human tumors are still limited: we and others recently showed that CDX-2 is ex- pressed in almost all colorectal adenocarcinomas and in a subset of gastric, pancreatic, and ovarian cancers, while it was not expressed in a large series of human tumors, including lung neoplasms. 2, 11, 15, 19, 23 This restricted pattern of expression, which is a characteristic of several other homeobox gene products, such as TTF-1, is very useful in differential diagnosis in a variety of settings, including the evaluation of cytologic specimens.
In the present study, we expand the knowledge about the possible use of CDX-2 as a diagnostic marker in the setting of WDNET. Our results demonstrate that CDX-2 strong expression is a highly sensitive marker for the identification of WDNET originating from the small intestine and appendix. CDX-2 is highly effective both on histologic and cytologic specimens. CDX-2 is expressed at low levels also in a significant percentage of pancreatic WDNETs. This phenomenon must be kept in mind when dealing with a metastatic WDNET of unknown primary site. However, CDX-2 immunoreactivity in pancreatic WDNET tumors is usually weak and heterogeneous, limited to the nucleus, thus making this pattern of reactivity quite different from that observed in ileal and appendiceal WDNETs.
Interestingly, CDX-2 expression correlated with the functional and clinical behavior of pancreatic WDNET: it was not expressed in functioning and in the majority of nonmetastatic tumors, whereas it was observed in one third of nonfunctioning and in almost half of tumors with metastatic behavior. The possible biologic and clinical relevance of these findings is unknown and deserves further investigation.
CDX-2 can be added to the limited list of markers that can be used in the differential diagnosis of WDNET of unknown primary origin. This list includes, beside specific hormones, the product of another homeobox gene, TTF-1. TTF-1 has been considered specific for lung WDNET, although there are major discrepancies in the literature regarding its sensitivity.
9,10,13,16,21 CDX-2 in combination with TTF-1 may help to correctly differentiate intestinal from lung WDNET.
CDX-2 expression was observed also in the majority of gastric and intestinal NECs, but, unexpectedly, also in a significant percentage of NEC of other sites. CDX-2 expression in these nongastrointestinal tumors was considered inappropriate because the organs where these tumor originate do not normally express CDX-2, nor do these tumors have any morphologic or biologic known feature of intestinal differentiation. This inappropriate expression limits its diagnostic utility in this setting. This pattern of CDX-2 expression parallels the similar abnormal expression of TTF-1 in non-lung NECs. 13, 17 The biologic significance of this inappropriate expression of both homeodomain proteins in NEC is at present unclear but suggests a complex deregulated expression of homeobox genes in NEC. In summary, our study expands the knowledge about the distribution of CDX-2 immunoreactivity in human neoplasms. In the setting of WDNET, strong nucleocytoplasmic reactivity is limited to tumors of the intestinal tract, while weak expression can be observed in subsets of aggressive pancreatic tumors. This restricted pattern of expression may have diagnostic value in the identification of the primary site of a metastatic WDNET. Conversely, a limited diagnostic role for CDX-2 is suggested in NEC because of its frequent inappropriate expression in NECs originating outside the gastrointestinal tract.
NOTE ADDED IN PROOF
Similar results on CDX-2 expression in NE cells and Tumors have been reported by La Rosa et al. (Virchows Archive, in press 2004). These Authors also underscore the relation between CDX-2 expression and the type of hormonal secretion of the NE cells and Tumors.
